Oncogenic MET alterations, including the overexpression of MET protein or MET gene alterations, such as mutations, amplifications, or fusions, cause dysregulation of the HGF/MET signaling pathway, and lead to a wide range of human cancers, including papillary renal cell carcinoma, gastric cancer, and non-small cell lung cancer, etc. [3,15]. This evidence concerns the gene MET and papillary renal cell carcinoma.